Insights
Research and perspectives on the data, AI and standards reshaping life sciences.
Blog3 min read5 Oct 2026
Is adding an agent to a broken process going to cut it?
AI models have improved enormously since 2023, and intelligence is becoming a commodity, but in pharma it only performs the way you expect with rules, context and limits.
Julieta Villafañe
Blog2 min read15 Sep 2026
No wind is a good wind: what AI needs before it can help you
AI is here to stay, but pointed at an organisation built around documents it returns marginal gains at best, because the model cannot work with information it never gets to see.
Julieta Villafañe
Article6 min read9 Sep 2026
AI implementation in pharma: a thought-provoking series
Why most AI pilots in pharma stall, what an agent needs to work reliably, what to ask before investing, and where the FDA and EMA are heading.
Julieta Villafañe
Article8 min read22 Jul 2026
From Documents to Data: The Prerequisite Behind Pharma's AI Implementation
The FDA and EMA are moving the industry away from documents and writing the rulebook around AI use, on 2026-2028 deadlines.
Julieta Villafañe
Blog2 min read9 Jul 2026
The information belongs to the product
Organise the information around the product, connected across areas, and a change shows everything it touches from the first evaluation.
Julieta Villafañe
Blog2 min read9 Jun 2026
The fire drill: one change in pharma, and the weekend it costs
A single change sets off a cascade of manual work, reconciliation and version drift; the complexity is real, the pain is not.
Julieta Villafañe
Questions and comments
Correspondence on these articles is welcome.
Get in touch